Next earnings date: 11 Aug 2025
TRACON Pharmaceuticals, Inc. – NASDAQ:TCON
TRACON Pharmaceuticals stock price today
$0.032
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
TRACON Pharmaceuticals stock price monthly change
-95.15%
month
TRACON Pharmaceuticals stock price quarterly change
-95.15%
quarter
TRACON Pharmaceuticals stock price yearly change
-82.51%
year
TRACON Pharmaceuticals key metrics
Market Cap | 109.72K |
Enterprise value | 34.42M |
P/E | -1.37 |
EV/Sales | N/A |
EV/EBITDA | -1.22 |
Price/Sales | N/A |
Price/Book | -5.87 |
PEG ratio | -0.08 |
EPS | -1.22 |
Revenue | N/A |
EBITDA | -5.16M |
Income | 1.74M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTRACON Pharmaceuticals stock price history
TRACON Pharmaceuticals stock forecast
TRACON Pharmaceuticals financial statements
| Jun 2023 | 9M | -6.28M | -69.84% |
|---|---|---|---|
| Sep 2023 | 0 | 10.76M | |
| Dec 2023 | 3.04M | 439K | 14.42% |
| Mar 2024 | 100K | -3.16M | -3168% |
| 2025 | 1.75M | -21.49M | -1228.29% |
|---|---|---|---|
| 2026 | 29.63M | -5.47M | -18.48% |
| 2027 | 76.24M | 29.14M | 38.22% |
| 2028 | 130.34M | 126.39M | 96.98% |
Analysts Price target
Financials & Ratios estimates
| 2024-08-13 | -1.05 | -0.94 |
|---|
| Jun 2023 | 12190000 | 27.92M | 229.11% |
|---|---|---|---|
| Sep 2023 | 9413000 | 12.49M | 132.76% |
| Dec 2023 | 10105000 | 10.91M | 108.01% |
| Mar 2024 | 9355000 | 11.11M | 118.83% |
| Jun 2023 | -5.85M | 0 | 1.04M |
|---|---|---|---|
| Sep 2023 | 15.05M | 0 | -9.09M |
| Dec 2023 | -522K | 0 | 1.32M |
| Mar 2024 | -2.54M | 0 | 1.87M |
TRACON Pharmaceuticals alternative data
| Aug 2023 | 18 |
|---|---|
| Sep 2023 | 18 |
| Oct 2023 | 18 |
| Nov 2023 | 18 |
| Dec 2023 | 18 |
| Jan 2024 | 18 |
| Feb 2024 | 18 |
| Mar 2024 | 17 |
| Apr 2024 | 17 |
| May 2024 | 17 |
| Jun 2024 | 17 |
| Jul 2024 | 17 |
TRACON Pharmaceuticals other data
26.13%
-19.62%
of TCON is owned by hedge funds
17
-15
5.46M
-4.35M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2022 | 12200 | 0 |
| Jun 2022 | 853408 | 0 |
| Jul 2022 | 31767 | 0 |
| Sep 2022 | 50911 | 0 |
| Oct 2022 | 22500 | 0 |
| Nov 2022 | 29100 | 0 |
| Dec 2022 | 194000 | 1539 |
| Jan 2023 | 6800 | 0 |
| Feb 2023 | 200 | 0 |
| Mar 2023 | 179308 | 0 |
| Apr 2023 | 50999 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | THEUER CHARLES director, officer.. | Common Stock | 47,000 | $0.75 | $35,250 | ||
Purchase | THEUER CHARLES director, officer.. | Common Stock | 3,999 | $0.66 | $2,639 | ||
Purchase | OPALEYE MANAGEMENT INC. 10 percent owner | Common Stock, par value $0.001 per share | 174,508 | $1.38 | $240,821 | ||
Purchase | THEUER CHARLES director, officer.. | Common Stock | 4,800 | $1.52 | $7,296 | ||
Purchase | THEUER CHARLES director, officer.. | Common Stock | 200 | $1.52 | $304 | ||
Purchase | THEUER CHARLES director, officer.. | Common Stock | 6,800 | $1.62 | $11,016 | ||
Purchase | BROWN SCOTT B. officer: Chief Financial Officer | Common Stock | 3,500 | $1.49 | $5,215 | ||
Purchase | THEUER CHARLES director, officer.. | Common Stock | 23,000 | $1.29 | $29,762 | ||
Purchase | OPALEYE MANAGEMENT INC. 10 percent owner | Common Stock, par value $0.001 per share | 27,500 | $1.24 | $34,045 | ||
Purchase | OPALEYE MANAGEMENT INC. 10 percent owner | Common Stock, par value $0.001 per share | 140,000 | $1.26 | $175,840 |
| Patent |
|---|
Application Filling date: 13 Nov 2019 Issue date: 19 Mar 2020 |
Application Filling date: 30 Sep 2019 Issue date: 13 Feb 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 5 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Charles P. Theuer M.D., Ph.D. (1964) Chief Executive Officer, Pres & Director | $905,380 |
Mr. Mark C. Wiggins M.B.A. (1956) Chief Bus. Officer | $543,990 |
Mr. Scott B. Brown CPA, M.S. (1981) Chief Financial Officer | $382,820 |
-
What's the price of TRACON Pharmaceuticals stock today?
One share of TRACON Pharmaceuticals stock can currently be purchased for approximately $0.03.
-
When is TRACON Pharmaceuticals's next earnings date?
TRACON Pharmaceuticals, Inc. is estimated to report earnings on Monday, 11 Aug 2025.
-
Does TRACON Pharmaceuticals pay dividends?
No, TRACON Pharmaceuticals does not pay dividends.
-
How much money does TRACON Pharmaceuticals make?
TRACON Pharmaceuticals has a market capitalization of 109.72K. TRACON Pharmaceuticals made a loss 3.59M US dollars in net income (profit) last year or -$0.94 on an earnings per share basis.
-
What is TRACON Pharmaceuticals's stock symbol?
TRACON Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "TCON".
-
What is TRACON Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of TRACON Pharmaceuticals?
Shares of TRACON Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are TRACON Pharmaceuticals's key executives?
TRACON Pharmaceuticals's management team includes the following people:
- Dr. Charles P. Theuer M.D., Ph.D. Chief Executive Officer, Pres & Director(age: 61, pay: $905,380)
- Mr. Mark C. Wiggins M.B.A. Chief Bus. Officer(age: 69, pay: $543,990)
- Mr. Scott B. Brown CPA, M.S. Chief Financial Officer(age: 44, pay: $382,820)
-
How many employees does TRACON Pharmaceuticals have?
As Jul 2024, TRACON Pharmaceuticals employs 17 workers.
-
When TRACON Pharmaceuticals went public?
TRACON Pharmaceuticals, Inc. is publicly traded company for more then 10 years since IPO on 30 Jan 2015.
-
What is TRACON Pharmaceuticals's official website?
The official website for TRACON Pharmaceuticals is traconpharma.com.
-
Where are TRACON Pharmaceuticals's headquarters?
TRACON Pharmaceuticals is headquartered at 4350 La Jolla Village Drive, San Diego, CA.
-
How can i contact TRACON Pharmaceuticals?
TRACON Pharmaceuticals's mailing address is 4350 La Jolla Village Drive, San Diego, CA and company can be reached via phone at 858 550 0780.
TRACON Pharmaceuticals company profile:
TRACON Pharmaceuticals, Inc.
traconpharma.comExchange:
NASDAQ
Full time employees:
17
Industry:
Biotechnology
Sector:
Healthcare
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
4350 La Jolla Village Drive
San Diego, CA 92122
San Diego, CA 92122
CIK: 0001394319
ISIN: US89237H2094
CUSIP: 89237H209
